# InMed Pharmaceuticals (NASDAQ: INM) Reports Promising Long-Term Results for Alzheimer’s Drug INM-901

InMed Pharmaceuticals (NASDAQ: INM), a biopharmaceutical company focused on developing proprietary small molecule drug candidates for diseases with high unmet needs, has announced promising outcomes from a long-term preclinical study of its Alzheimer’s Disease (“AD”) drug candidate, INM-901. These new findings confirm and expand upon results from a previous short-term pilot study (https://ibn.fm/eASUI). The long-term […] 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/ibn-prem/inmed-pharmaceuticals-nasdaq-inm-reports-promising-long-term-results-for-alzheimers-drug-inm-901/)
                    

[Newsramp.com TLDR](None) 



[Reddit Post](https://www.reddit.com/r/HealthCareNewsInfo/comments/1f2hck4/inmed_pharmaceuticals_announces_promising_results/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/248/27/echocQN1.webp)